Switch theme
Sign up to access all valuation multiples
Beijing Wandong Medical Technology Co Ltd is engaged in the development, manufacture, and distribution of medical equipment. Its products consist of radiological imaging equipment, including angiographic and cardiac systems, digital direct radiography (DR) imaging equipment, high frequency diagnostic systems, high frequency radiographic systems, conventional x-ray diagnostic equipment and high frequency mobile units, magnetic resonance imaging (MRI) equipment, as well as digital medical image management systems, among others. The company is also engaged in providing maintenance services.
1997
964
LTM Revenue $236M
LTM EBITDA $22.1M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wandong Medical has a last 12-month revenue (LTM) of $236M and a last 12-month EBITDA of $22.1M.
In the most recent fiscal year, Wandong Medical achieved revenue of $212M and an EBITDA of $28.8M.
Wandong Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wandong Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $236M | XXX | $212M | XXX | XXX | XXX |
| Gross Profit | $87.1M | XXX | $77.3M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $22.1M | XXX | $28.8M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $24.0M | XXX | $15.9M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $22.9M | XXX | $21.8M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wandong Medical's stock price is CNY 18 (or $3).
Wandong Medical has current market cap of CNY 13.0B (or $1.8B), and EV of CNY 9.6B (or $1.3B).
See Wandong Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.8B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wandong Medical has market cap of $1.8B and EV of $1.3B.
Wandong Medical's trades at 6.3x EV/Revenue multiple, and 46.4x EV/EBITDA.
Equity research analysts estimate Wandong Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wandong Medical has a P/E ratio of 78.4x.
See valuation multiples for Wandong Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 60.5x | XXX | 46.4x | XXX | XXX | XXX |
| EV/EBIT | 55.6x | XXX | 84.1x | XXX | XXX | XXX |
| EV/Gross Profit | 15.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 78.4x | XXX | 82.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 53.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWandong Medical's last 12 month revenue growth is 28%
Wandong Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Wandong Medical's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wandong Medical's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wandong Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | -10% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wandong Medical acquired XXX companies to date.
Last acquisition by Wandong Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Wandong Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wandong Medical founded? | Wandong Medical was founded in 1997. |
| Where is Wandong Medical headquartered? | Wandong Medical is headquartered in China. |
| How many employees does Wandong Medical have? | As of today, Wandong Medical has 964 employees. |
| Is Wandong Medical publicy listed? | Yes, Wandong Medical is a public company listed on SHG. |
| What is the stock symbol of Wandong Medical? | Wandong Medical trades under 600055 ticker. |
| When did Wandong Medical go public? | Wandong Medical went public in 1997. |
| Who are competitors of Wandong Medical? | Similar companies to Wandong Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Wandong Medical? | Wandong Medical's current market cap is $1.8B |
| What is the current revenue of Wandong Medical? | Wandong Medical's last 12 months revenue is $236M. |
| What is the current revenue growth of Wandong Medical? | Wandong Medical revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Wandong Medical? | Current revenue multiple of Wandong Medical is 5.7x. |
| Is Wandong Medical profitable? | Yes, Wandong Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wandong Medical? | Wandong Medical's last 12 months EBITDA is $22.1M. |
| What is Wandong Medical's EBITDA margin? | Wandong Medical's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Wandong Medical? | Current EBITDA multiple of Wandong Medical is 60.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
